AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…

Read More

Medicare Advantage CEO: My Baby is Ugly…(video)

Earlier this month Sachin Jain, CEO of SCAN Health Plan, a nonprofit Medicare Advantage company, provided some refreshing straight talk on what is wrong with MA while stressing that it is far better than traditional Medicare for seniors. The post Medicare Advantage CEO: My Baby is Ugly…(video) appeared first on MedCity News.

Read More

Clinician Adoption: How HealthTech Can Overcome Key Barriers

Even the most promising medical advancements struggle to take off in real-world settings without clinician buy-in. Here are some key factors that affect clinician adoption and ways healthtech companies can better position their innovations for success. The post Clinician Adoption: How HealthTech Can Overcome Key Barriers appeared first on MedCity News.

Read More